Features | Partner Sites | Information | LinkXpress
Sign In

Oncolab Exhibits Pioneering AMAS Cancer Test at AACC

By Labmedica International staff writers
Posted on 29 Jul 2014
Image: The AMAS test by Oncolab is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility (Photo courtesy of Oncolab).
Image: The AMAS test by Oncolab is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility (Photo courtesy of Oncolab).
The Oncolab (Boston, MA, USA) laboratory-developed AMAS cancer test is making its AACC debut at this year's 2014 conference. To date, the test, which is a serum-based in vitro immunoassay, has been run for over 60,000 patients and appears to be an emerging tool in the fight against cancer recurrence as well as detection.

There are an estimated 17 million cancer survivors in the US alone, hence there is a race to develop better technologies for identifying whether a cancer has begun to recur, and if so at what rate. There is a clear trend towards the use of immunoassays in cancer diagnostics, as immunotherapy for treatment. The AMAS test fits into these trends by measuring the level of a specific antibody, Anti-Malignin Antibody, which is thought to be produced by the body's immune system in response to nearly all forms of cancer.

Most other cancer immunoassays measure circulating cancer antigens, which become elevated later than the antibody measured in the AMAS test. Therefore, the AMAS Test helps to pick up recurrence at an early stage when levels of anti-malignin antibody are often elevated early in the occurrence and recurrence of cancer. This is a distinctive capability—false positive and false negative rates are under 10%. While the AMAS test does provide guidance to the likely location of the cancer, new high-resolution imaging techniques, more location-specific cancer tests, and clinical signs help the clinician provide patients with a fuller picture of the disease.

Currently, Oncolab provides the test via submission of samples to its CLIA-certified laboratory in Boston. Serum samples must be shipped via overnight courier, using a standardized shipping container and tubes provided at no cost by Oncolab, dry ice obtained at the lab while doing the blood draw, and separation to serum. The test is approved by the US Food and Drug Administration (FDA) and reimbursed by Medicare.

Today, the majority of samples being run are drawn in the US and Canada; overseas labs can also ship samples and are urged to contact Oncolab to get a technical and business relationship started.

The AMAS test, by Oncolab, is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility in Boston. The test is able to detect early cases of cancer recurrence, a major concern for 17 million Americans. This year is the company's debut at the AACC (American Association for Clinical Chemistry), being held in Chicago - booth #4051.

Related Links:

Oncolab



KARL HECHT GMBH & CO KG
CELLAVISION AB
MEDLAB Asia

Channels

Genetic Tests

view channel
Image: For each chromosome, key SNPs are displayed above the chromosome and non-key SNPs below the chromosome, enabling users to determine the accuracy of haploblock calling. SNPs failed to be called are displayed as white points in the middle of the chromosome (Photo courtesy of Illumina).

Karyomapping Proposed as Alternative to Preimplantation Genetic Diagnosis for Evaluation of IVF Embryos

British researchers have suggested that karyomapping is a viable and cost-effective method for detecting a wide range of genetic diseases in IVF (in vitro fertilization) embryos. Preimplantation Genetic... Read more

Industry News

view channel
Image: Positive case of lung tissue stained for ALK with VENTANA ALK (D5F3) CDx Assay, a companion diagnostic immunohistochemical test in the final stages of the FDA premarket approval process (Photo courtesy of Ventana Medical Systems and PRNewsFoto).

Premarket Approval Sought for CDx Test to Benefit Lung Cancer Patients

Ventana Medical Systems, Inc. (Tucson, AZ, USA) has announced its US Food & Drug Administration (FDA) final stage submission for premarket approval (PMA) of its companion diagnostic (CDx) immunohistochemistry... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.